NASDAQ: DVAXDynavax Technologies Corp Stock
$11.11-0.17 (-1.51%)
Updated May 17, 2024
DVAX Price
$11.11
Fair Value Price
N/A
Market Cap
$1.45B
52 Week Low
$10.48
52 Week High
$15.15
P/E
158.71x
P/B
2.35x
P/S
6.84x
PEG
N/A
Dividend Yield
N/A
Revenue
$236.15M
Earnings
$9.22M
Gross Margin
80.3%
Operating Margin
6.19%
Profit Margin
3.9%
Debt to Equity
0.6
Operating Cash Flow
$56M
Beta
1.1
Next Earnings
May 23, 2024
Ex-Dividend
N/A
Next Dividend
N/A
DVAX Overview
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how DVAX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DVAX was unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
DVAX is poor value based on its earnings relative to its share price (158.71x), compared to the US market average (30.97x)
P/E vs Market Valuation
DVAX is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more DVAX due diligence checks available for Premium users.
Be the first to know about important DVAX news, forecast changes, insider trades & much more!
DVAX News
Valuation
DVAX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
158.71x
Industry
-1.01x
Market
30.97x
DVAX is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
DVAX is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
DVAX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.35x
Industry
2.2x
DVAX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DVAX's financial health
Profit margin
Revenue
$50.8M
Net Income
-$8.7M
Profit Margin
-17.2%
DVAX's Earnings (EBIT) of $14.62M... subscribe to Premium to read more.
Interest Coverage Financials
DVAX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$986.6M
Liabilities
$368.1M
Debt to equity
0.6
DVAX's short-term assets ($851.29M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DVAX's short-term assets ($851.29M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DVAX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
DVAX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$16.7M
Investing
$2.8M
Financing
-$4.2M
DVAX's operating cash flow ($56.26M)... subscribe to Premium to read more.
Debt Coverage Financials
DVAX vs Pharmaceutical Stocks
Dynavax Technologies Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.